Monitor for interim Phase 1 data from Neurosterix in mid-2026, which could revalue Addex's stake. However, given the early-stage nature and lack of near-term revenue implications, expect limited immediate stock price impact unless results exceed expectations.
Price Chart
Executive Summary
Addex Therapeutics announced that its spin-out company Neurosterix is on track to complete a Phase 1 clinical study of NTX-253, an M4 receptor PAM for schizophrenia, in Q2 2026. The study includes both healthy volunteers and patients with stable schizophrenia, with data expected to support future development. Addex retains a 20% equity stake in Neurosterix.
Key Facts
- Neurosterix, a spin-out of Addex, is advancing NTX-253 through a Phase 1 clinical trial with completion expected in Q2 2026.
- The Phase 1 study includes single and multiple ascending dose components, with cohorts in both healthy adults and patients with stable schizophrenia.
- Study design includes food-effect and cerebrospinal fluid (CSF) assessments to evaluate CNS exposure.
- Neurosterix raised $65 million in Series A financing in April 2024, led by Perceptive Advisors.
- Addex retains a 20% equity interest in Neurosterix but has no direct financial or operational control.
Financial Impact
No direct financial impact disclosed; potential future value tied to milestone achievements or equity appreciation in Neurosterix.
Risk Factors
- Clinical trial delays or safety issues in the Phase 1 study could negatively impact sentiment.
- Low probability of near-term monetization given the early development stage and Addex's minority stake.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002661 |
| Document: f6k_042326.htm | 0001171843-26-002661 |
| Document: 0001171843-26-002661-index-headers.html | 0001171843-26-002661 |
| Document: 0001171843-26-002661-index.html | 0001171843-26-002661 |
| Document: 0001171843-26-002661.txt | 0001171843-26-002661 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 6-K | $3.18 | awaiting T+60 | — | $2.99 (−5.97%) |
Oct 2, 2026 25d ago | 6-K | $3.07 | awaiting T+60 | — | $2.99 (−2.61%) |
Sep 28, 2026 29d ago | 6-K | $2.81 | awaiting T+60 | — | $2.99 (−6.41%) |
Sep 25, 2026 4w ago | 6-K | $3.65 | awaiting T+60 | — | $2.99 (−18.08%) |
Aug 26, 2026 8w ago | 6-K | $4.23 | awaiting T+60 | — | $2.99 (+29.31%) |
Jul 8, 2026 15w ago | 6-K | $5.89 $2.98 | ▼ −49.41% | ▼ −51.90% | $2.99 (−49.24%) |
Jun 30, 2026 17w ago | 6-K | $5.70 $3.45 | ▲ +39.47% | ▲ +42.29% | $2.99 (+47.54%) |
Jun 25, 2026 17w ago | 6-K | $5.94 $3.40 | ▲ +42.76% | ▲ +46.49% | $2.99 (+49.66%) |
May 15, 2026 23w ago | 20-F | $6.83 $5.95 | ▲ +12.88% | ▲ +17.74% | $2.99 (+56.22%) |
Apr 23, 2026 26w ago | 6-K | $6.14 $5.60 | ▼ −8.79% | ▼ −13.81% | $2.99 (−51.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers